Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Development of targeted drugs for diabetic retinopathy using Mendelian randomized pharmacogenomics

Liu G., Tian M., Li X., Wang X., Zhang S., Bai G.

Laboratory Study on Hip, published in Front Endocrinol (Lausanne) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Endocrinol (Lausanne) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41079190
PMCID
PMC12512044
DOI
10.3389/fendo.2025.1632691

Abstract (original English)

Purpose This study aims to utilize genetic instrumental variables - protein quantitative trait loci (pQTL), and through analysis methods such as Mendelian randomization (MR), systematically screen and validate druggable proteins that have a causal relationship with diabetic retinopathy (DR), and further explore related drug targets, providing genetic evidence and new directions for the drug development of this disease. Methods The research was based on large-scale public databases to conduct two-sample Mendelian randomization (MR) analysis. Firstly, 511 encoded proteins were selected from the known 4,479 druggable genes as initial exposure factors, with the summary data of GWAS for diabetic retinopathy as the outcome. MR analysis was conducted using the inverse variance weighted (IVW) method and the Wald ratio method, and strict screening was performed through Bonferroni correction. For the significantly associated proteins, heterogeneity tests, pleiotropy tests, leave-one-out analysis, and Steiger directionality tests were further conducted to verify the robustness of the results. Additionally, summary MR (SMR) analysis and colocalization analysis (coloc) were used to confirm the reliability of the causal relationship. Finally, a protein-protein interaction (PPI) network was constructed using the STRING database, and potential targeted drugs were mined from the DrugBank and DS

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansDiabetic RetinopathyPharmacogeneticsPolymorphism, Single NucleotideQuantitative Trait LociGenome-Wide Association StudyMendelian Randomization AnalysisProtein Interaction MapsDrug Development

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research